Advanced search×

Should we follow-up serum testosterone in patients with advanced prostate cancer?

Perachino M

Expert Rev Anti Infect Ther 10(7):1031-5 (2010) PMID 20645692

Agonistic analogs of luteinizing hormone-releasing hormones are indicated for the palliative treatment of metastatic prostate cancer. While the prognostic role of prostate-specific antigen in patients submitted to androgen-deprivation therapy has been extensively investigated in these patients, there is no consensus about the utility of serum testosterone measurements during follow-up and about their possible prognostic value. Recent reports have shown that testosterone levels might be directly related to survival and risk of death. These results need to be confirmed by further prospective studies. Given this concept, lowering testosterone as much as possible should be the goal of androgen-deprivation therapy in patients with metastatic prostate cancer, as this may have an impact on patient survival.

DOI: 10.1586/era.10.92
Version: za2963e q8za6 q8zb8 q8zcf q8zd0 q8zed q8zf4 q8zgb

Similar articles you may find interesting…

  1. Blockade of testicular and adrenal androgens in prostate cancer treatment.
    Fernand F Labrie

    Nat Rev Urol 8(2):73-85 (2011) PMID 21243019

    Prostate cancer is the most hormone sensitive of all cancers. However, any hormonal therapeutic strategy must take into account the fact that two almost equivalent sources of androgens act in the prostate, namely testosterone of testicular origin, and the locally produced androgens t...
  2. Modeling prostate cancer in mice: limitations and opportunities.
    Patrick J PJ Hensley and Natasha N Kyprianou

    J Androl 33(2):133-44 (2012) PMID 21680808

    The complex dynamics of the tumor microenvironment and prostate cancer heterogeneity have confounded efforts to establish suitable preclinical mouse models to represent human cancer progression from early proliferative phenotypes to aggressive, androgen-independent and invasive metas...
  3. The development of androgen-independent prostate cancer.
    B J BJ Feldman and D D Feldman

    Nat Rev Cancer 1(1):34-45 (2001) PMID 11900250

    We predict that understanding the pathways that lead to the development of androgen-independent prostate cancer will pave the way to effective therapies for these, at present, untreatable cancers....